US-based technology and service provider Thread and CureClick have announced a new partnership to accelerate recruitment for decentralised clinical trials (DCTs).
The partnership is focused on engaging social media influencers to increase recruitment outcomes in DCTs.
Influencers can combine THREAD’s platform with CureClick’s more than 100,000 patient activists and advocates network to highlight potentially life-saving DCTs within targeted social media networks.
This helps to achieve increased trial enrollment, retention and satisfaction rates.
CureClick CEO Fabio Gratton said: “We are excited for this partnership to advance recruitment for DCTs.
“THREAD is the leading DCT provider, and by joining forces, we can better fulfill our mission to help life science organisations recruit patients faster while ensuring they have the best possible experience at every step.”
By increasing clinical trial awareness and accelerating patient recruitment, CureClick will enable trusted online community members to find and spread accurate information easily across their social networks.
CureClick patient activists will deliver eligible participants to THREAD’s automated participant recruitment and onboarding solution, through this partnership.
THREAD CEO John Reites said: “We have great admiration for CureClick’s ability to drive exceptional recruitment outcomes through its ambassador network of patient activists.
“Having worked successfully with CureClick on several studies in the past, we are excited to deepen our collective impact on DCTs through a more formal partnership.”
The company recently improved its DCT platform with a configurable, automated participant recruitment and onboarding solution where sponsors and CROs can create patient-facing websites.
These websites guide potential participants through a simple automated recruitment and onboarding process.
CureClick is a community-powered platform that revolutionises the recruitment of participants for clinical trials.